Mounjaro 2.5 mg and weight loss: what to expect from the starting dose

Why the trial evidence doesn't score weight loss at 2.5 mg

SURMOUNT-1 (the pivotal phase-3 trial that underpins Mounjaro's UK licence) randomised 2,539 adults with obesity and measured outcomes over 72 weeks, not over four. The figures reported in the NEJM's SURMOUNT-1 publication reflect participants who escalated through the full titration schedule to maintenance doses of 5, 10, or 15 mg. Average body-weight reduction of around 20–21% at 15 mg is the headline. The 2.5 mg phase simply doesn't feature as a standalone data point, because that was never its purpose.

That design choice reflects the medicine's mechanism. Tirzepatide activates both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite signals. At 2.5 mg, receptor engagement is real but modest. The main thing happening physiologically is adaptation, your gut, your pancreas and your appetite-regulating systems are meeting a new signal for the first time. Beginning at a low dose significantly reduces the chance of severe nausea during those first weeks.

So if you've started Mounjaro and the scales haven't moved much after week three or four, that's consistent with the clinical evidence. Lack of weight loss on Mounjaro 2.5 mg is not a sign the medicine isn't working. It's a sign the medicine is doing exactly what it was designed to do at this stage. The NHS tirzepatide information page confirms this graduated approach.

What patients typically notice (and don't notice) at 2.5 mg

Most people report some reduction in appetite within the first week or two, even at the starter dose. Portions feel smaller. The urge to snack between meals diminishes a little. For some this is subtle; for others it's the first time in years their hunger has felt manageable. What most people don't notice at 2.5 mg is significant weight change, and that's fine.

The side effects most commonly reported at this stage are gastrointestinal: nausea, loose stools, and occasionally constipation or reflux. These tend to be mild and settle within a couple of weeks for most people. They're also a useful signal. If they're entirely absent, titration to 5 mg will probably be straightforward. If they're noticeable, the four-week window gives time for things to settle before the dose increases.

What you won't need to manage at 2.5 mg is complex self-administration. The Mounjaro KwikPen holds four weekly doses. Inject once a week (abdomen, thigh, or upper arm, rotating the site) then store the pen back in the fridge between uses. If you order through a regulated UK service and are approved, the pen arrives via DPD in plain, unbranded packaging, with tracking sent to your phone the moment it's dispatched.

For a direct comparison of what changes between the 2.5 mg and 5 mg phases, see our guide to 2.5 mg vs 5 mg.

When to expect weight loss to become visible, and what drives it

The clearest weight-loss results in tirzepatide trials begin to emerge after people have moved beyond the starter phase and are spending meaningful time at therapeutic doses. For most participants in SURMOUNT-1, that meant months of treatment, not weeks. Individual responses vary considerably. Some people see movement on the scales during the 2.5 mg period; many don't. Neither pattern predicts long-term outcome.

What does correlate with outcome is the quality of the wraparound approach. Tirzepatide is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them. The appetite reduction the medicine creates is most useful when it's channelled into sustainable eating habits rather than simply smaller portions of the same foods. Protein adequacy, hydration and maintaining muscle mass through some form of resistance activity all matter as the weight comes off.

If you're concerned that weight loss on Mounjaro 2.5 mg hasn't started after four weeks, that concern is worth raising with your prescriber before the dose increases, not because something is wrong, but because your prescriber can put the picture in clinical context. Read more about how weight loss typically progresses as doses increase beyond the starter phase, including what to expect when you reach 5 mg and the changes it tends to bring and above.

Cost is often part of the conversation here too. Private treatment represents a real monthly outlay, and understanding what you're paying for at each stage matters. If you're planning ahead, it's also worth reading about how Mounjaro pricing has changed, so you can budget accurately for the full titration journey. Our Mounjaro price context page sets out what legitimate private prescriptions in the UK typically include.

Safety signals worth knowing at the starter dose

The MHRA's monitoring of tirzepatide covers the full dosing range, including 2.5 mg. Acute pancreatitis is a rare but serious potential side effect across all GLP-1 medicines: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention rather than waiting for your next scheduled review. Report any unexpected or persistent side effects through the MHRA Yellow Card scheme.

Tirzepatide is not recommended during pregnancy, whilst breastfeeding, or if you're actively trying to conceive. It is not licensed for use in under-18s. Women using oral contraceptives should discuss with their prescriber whether a non-oral method is needed as a backup during the first four weeks of treatment, as there is some evidence that pill absorption may be affected during this period. These are conversations to have during your clinical consultation, not to navigate alone.

If you're weighing up tirzepatide more broadly and want a fuller picture of the clinical evidence, the Mounjaro overview covers eligibility, how the medicine works, and the NHS vs private access routes in one place. Our clinical team reviews every consultation personally before any prescription is issued.